Haemonetics (NYSE:HAE) Stock Price Expected to Rise, Barrington Research Analyst Says

Haemonetics (NYSE:HAE) had its target price hoisted by equities researchers at Barrington Research from $140.00 to $145.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research‘s price objective would indicate a potential upside of 21.55% from the company’s previous close.

Several other research analysts have also issued reports on HAE. Wall Street Zen upgraded Haemonetics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Citigroup increased their target price on Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Raymond James Financial raised their target price on Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, September 3rd. Mizuho set a $165.00 target price on Haemonetics in a research report on Thursday. Finally, BTIG Research upped their price target on Haemonetics from $130.00 to $142.00 and gave the company a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Haemonetics currently has an average rating of “Moderate Buy” and a consensus price target of $114.67.

Haemonetics Price Performance

Haemonetics stock traded down $4.82 during trading hours on Friday, hitting $119.29. 455,632 shares of the stock were exchanged, compared to its average volume of 809,977. The stock has a market capitalization of $5.43 billion, a P/E ratio of 58.43, a P/E/G ratio of 2.55 and a beta of 0.63. The business’s 50-day moving average is $111.18 and its two-hundred day moving average is $79.80. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08. Haemonetics has a 12 month low of $51.00 and a 12 month high of $132.00.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The business had revenue of $357.76 million for the quarter, compared to the consensus estimate of $345.15 million. During the same quarter in the prior year, the company earned $1.27 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. Equities research analysts expect that Haemonetics will post 5.29 EPS for the current fiscal year.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its holdings in shares of Haemonetics by 21.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after buying an additional 233,119 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in Haemonetics by 1,191.9% during the third quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier’s stock worth $47,762,000 after buying an additional 418,470 shares during the last quarter. Bank of America Corp DE acquired a new position in Haemonetics during the second quarter worth $33,326,000. London Co. of Virginia raised its position in Haemonetics by 33.9% during the first quarter. London Co. of Virginia now owns 352,807 shares of the medical instruments supplier’s stock worth $19,884,000 after acquiring an additional 89,242 shares in the last quarter. Finally, William Blair Investment Management LLC bought a new stake in Haemonetics during the second quarter worth $24,906,000. Institutional investors own 99.67% of the company’s stock.

Key Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Fiscal Q2 revenue was $357.8 million, above the roughly $345 million consensus and up 9.4% year over year. Adjusted earnings were $1.35 per share, topping the $1.29 estimate and rising from $1.27 a year earlier. Haemonetics Q2 results and guidance
• Positive Sentiment: Management raised its FY2027 revenue and organic-growth outlook, projecting organic growth of 6%–9%. That signals confidence in continued demand and execution. FY2027 growth outlook and CSL Persona PLUS rollout
• Positive Sentiment: BTIG raised its price target to $142 from $130 and maintained a Buy rating, adding a favorable analyst signal. BTIG analyst ratings
• Neutral Sentiment: Haemonetics plans to scale the CSL Persona PLUS rollout through calendar 2027. This could support future growth, though the rollout’s pace and execution remain factors to monitor. CSL Persona PLUS rollout
• Negative Sentiment: The earnings-call coverage highlighted tradeoffs between growth and margins. Investors may be focused on the cost or profitability implications of pursuing growth and scaling the rollout, despite the quarter’s beat. Earnings call growth and margin tradeoffs

About Haemonetics

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.